Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 291

1.

[Pathophysiology and therapy of castration-resistant prostate cancer].

Merseburger AS, Kuczyk MA, Wolff JM.

Urologe A. 2013 Feb;52(2):219-25. doi: 10.1007/s00120-012-3054-8. Review. German.

PMID:
23160609
2.

[Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].

Pinto F, Calarco A, Totaro A, Sacco E, Volpe A, Racioppi M, D'Addessi A, Bassi PF.

Urologia. 2010 Apr-May;77(2):71-83. Review. Italian.

PMID:
20890863
3.

[Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].

Neuzillet Y, Flamand V, Lebdai S, Villers A, Lebret T.

Prog Urol. 2013 Oct;23 Suppl 1:S34-43. doi: 10.1016/S1166-7087(13)70044-7. Review. French.

PMID:
24314737
4.

[Castration resistant prostate cancer 2011].

Miller K.

Aktuelle Urol. 2011 Mar;42(2):95-102. doi: 10.1055/s-0031-1271399. Epub 2011 Mar 24. Review. German.

PMID:
21437832
5.

Prostate cancer-from steroid transformations to clinical translation.

Chang KH, Sharifi N.

Nat Rev Urol. 2012 Dec;9(12):721-4. doi: 10.1038/nrurol.2012.175. Epub 2012 Oct 2.

PMID:
23027067
6.

The role of enzalutamide in the treatment of castration-resistant prostate cancer.

Rawlinson A, Mohammed A, Miller M, Kunkler R.

Future Oncol. 2012 Sep;8(9):1073-81. doi: 10.2217/fon.12.99. Review.

PMID:
23030482
7.

Enzalutamide for the treatment of castration-resistant prostate cancer.

Ha YS, Goodin S, DiPaola RS, Kim IY.

Drugs Today (Barc). 2013 Jan;49(1):7-13. doi: 10.1358/dot.2013.49.1.1910724. Review.

PMID:
23362491
8.

Changing therapeutic paradigms in castrate-resistant prostate cancer.

Zivi A, Massard C, De-Bono J.

Clin Genitourin Cancer. 2010 Dec 1;8(1):17-22. doi: 10.3816/CGC.2010.n.003. Review.

PMID:
21208851
9.

[Management of enzalutamide, a new hormonal therapy].

Beuzeboc P, Benderra MA, de La Motte Rouge T.

Bull Cancer. 2014 Jan 1;101(1):107-12. doi: 10.1684/bdc.2013.1880. French.

PMID:
24491670
10.

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Sharifi N.

Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Review.

PMID:
20524793
11.

Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.

Payne H, Bahl A, Mason M, Troup J, De Bono J.

BJU Int. 2012 Sep;110(5):658-67. doi: 10.1111/j.1464-410X.2011.10886.x. Epub 2012 Mar 19.

12.

Landmarks in hormonal therapy for prostate cancer.

Hammerer P, Madersbacher S.

BJU Int. 2012 Oct;110 Suppl 1:23-9. doi: 10.1111/j.1464-410X.2012.11431.x. Review.

13.

The utility of prostate-specific antigen in the management of advanced prostate cancer.

Crawford ED, Bennett CL, Andriole GL, Garnick MB, Petrylak DP.

BJU Int. 2013 Sep;112(5):548-60. doi: 10.1111/bju.12061. Epub 2013 Jul 4. Review.

14.

Agents that target androgen synthesis in castration-resistant prostate cancer.

Ferraldeschi R, de Bono J.

Cancer J. 2013 Jan-Feb;19(1):34-42. doi: 10.1097/PPO.0b013e31827e0b6f. Review.

PMID:
23337755
15.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

16.

[New endocrine treatments prolong survival of patients with castration-resistant prostate cancer].

Brasso K, Thomsen FB, Berg KD, Røder MA, Iversen P.

Ugeskr Laeger. 2013 Sep 30;175(40):2328-32. Review. Danish.

PMID:
24079321
17.

Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer.

Hoffman-Censits J, Kelly WK.

Clin Cancer Res. 2013 Mar 15;19(6):1335-9. doi: 10.1158/1078-0432.CCR-12-2910. Epub 2013 Jan 8.

18.

Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.

Eur Urol. 2015 Mar;67(3):470-9. doi: 10.1016/j.eururo.2014.09.049. Epub 2014 Oct 8. Review.

PMID:
25306226
19.

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS.

Eur J Cancer. 2014 Jan;50(1):78-84. doi: 10.1016/j.ejca.2013.08.020. Epub 2013 Sep 25.

PMID:
24074764
20.

New agents in the arsenal to fight castrate-resistant prostate cancer.

Ezzell EE, Chang KS, George BJ.

Curr Oncol Rep. 2013 Jun;15(3):239-48. doi: 10.1007/s11912-013-0305-9. Review.

PMID:
23440553
Items per page

Supplemental Content

Write to the Help Desk